Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Before the JAK inhibitors came out, we had ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

Patients with rheumatoid arthritis (RA) whose symptoms improved after they started taking nonbiologic disease-modifying antirheumatic drugs (DMARDs) also demonstrated restored balance in their oral ...

Our objective was to describe characteristics and compare clinical and patient-reported outcomes (PROs) for disease-modifying antirheumatic drug (DMARD)-naive patients with psoriatic arthritis (PsA) ...

Commenting about the trial during an interview, session cochair Dr Georg Schett (Medical University of Vienna, Austria) called the trial "an important story." He added that the findings confirm the ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Minimal disease activity (MDA) was more likely in people with psoriatic arthritis (PsA) when they initiated a disease-modifying anti-rheumatic drug (DMARD) earlier rather than later. That's according ...

The latest update says that Janus kinase (JAK) inhibitors should only be used if risk factors for cardiovascular disease or cancer have been considered, and that biologics are preferred. EULAR ...